

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 73045

Title: Camrelizumab-induced anaphylactic shock in an esophageal squamous cell

carcinoma patient: A case report and review of literature

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05830717 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Portugal

Author's Country/Territory: China

Manuscript submission date: 2021-11-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-11-11 12:03

Reviewer performed review: 2021-11-21 18:15

Review time: 10 Days and 6 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No



Baishideng Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

It is an interesting, updated and well-written case report. The authors discussed exhaustively the risk factors to develop a drug induced anaphylactic shock and it was very interesting to read the discussion about re-introducing or not camrelizumab after this serious adverse event. However, the authors don't tell about what they did specifically in this case. If they switch immunotherapy, which drug was chosen? And how did it go? Did they used some pre-medication?



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 73045

Title: Camrelizumab-induced anaphylactic shock in an esophageal squamous cell

carcinoma patient: A case report and review of literature

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05265688 Position: Peer Reviewer Academic degree: PhD

Professional title: Postdoctoral Fellow

Reviewer's Country/Territory: Tunisia

Author's Country/Territory: China

Manuscript submission date: 2021-11-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-11-29 17:26

Reviewer performed review: 2021-12-04 19:31

Review time: 5 Days and 2 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No



Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

"Camrelizumab-induced anaphylactic shock in an esophageal squamous cell carcinoma patient: a case report and review of literature" was a good publication in general. I recommended it for publication.